All Studies Meta Analysis Recent:

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Cassione et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717

May 2020

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020

^*, now with p < 0.00000000001 from 418 studies, recognized in 46 countries.

Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments. ^* >10% efficacy, ≥3 studies.

5,000+ studies for 104 treatments. c19hcq.org

Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed cases. No mortality, one ICU case. 7 patients had no symptoms despite contact with a COVID-19 patient.

No adjustment for concomitant medications or severity of SLE. Confounding by indication.

This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.

Important missing comments or errors? Let us know.

risk of case, 49.6% higher, RR 1.50, p = 0.59, treatment 10 of 127 (7.9%), control 2 of 38 (5.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Cassione et al., 12 May 2020, retrospective, Italy, peer-reviewed, survey, median age 52.5, 6 authors.

This Paper HCQ All

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Professor Carlomaurizio Montecucco, Lorenzo Cavagna

Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717

Handling editor Josef S Smolen Acknowledgements The authors wish to thank Dr Luciano Perotti from the ICU department of our Hospital for his invaluable contribution to the good outcome of the admitted SLE patient.

References

Ferner, Aronson, Chloroquine and hydroxychloroquine in covid-19, BMJ, doi:10.1136/bmj.m1432

Hollander, Carr, Virtually perfect? telemedicine for Covid-19, N Engl J Med, doi:10.1056/NEJMp2003539

Joob, Wiwanitkit, Sle, hydroxychloroquine and NO SLE patients with COVID-19: a comment, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217506

Mathian, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566

Monti, Balduzzi, Delvino, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217424

Remuzzi, Remuzzi, COVID-19 and Italy: what next?, Lancet, doi:10.1016/S0140-6736(20)30627-9

{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T07:53:04Z', 'timestamp': 1712562784455}, 'reference-count': 7, 'publisher': 'BMJ', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 5, 12]], 'date-time': '2020-05-12T00:00:00Z', 'timestamp': 1589241600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://bmj.com/coronavirus/usage'}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.1136/annrheumdis-2020-217717', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 23]], 'date-time': '2020-05-23T21:15:14Z', 'timestamp': 1590268514000}, 'page': '1382-1383', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 77, 'title': 'COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by ' 'telemedicine', 'prefix': '10.1136', 'volume': '79', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6578-6938', 'authenticated-orcid': False, 'given': 'Emanuele', 'family': 'Bozzalla Cassione', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5042-1282', 'authenticated-orcid': False, 'given': 'Giovanni', 'family': 'Zanframundo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandro', 'family': 'Biglia', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2557-8514', 'authenticated-orcid': False, 'given': 'Veronica', 'family': 'Codullo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlomaurizio', 'family': 'Montecucco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lorenzo', 'family': 'Cavagna', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2020, 5, 12]]}, 'reference': [ { 'key': '2021051223100650000_79.10.1382.1', 'doi-asserted-by': 'crossref', 'first-page': '1225', 'DOI': '10.1016/S0140-6736(20)30627-9', 'article-title': 'COVID-19 and Italy: what next?', 'volume': '395', 'author': 'Remuzzi', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '2021051223100650000_79.10.1382.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217424'}, { 'key': '2021051223100650000_79.10.1382.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217506'}, { 'key': '2021051223100650000_79.10.1382.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217566'}, { 'key': '2021051223100650000_79.10.1382.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMp2003539'}, { 'key': '2021051223100650000_79.10.1382.6', 'unstructured': 'Epidemia COVID-19. Available: ' 'https://www.epicentro.iss.it/coronavirus/bollettino/Bolletino-sorveglianza-integrata-COVID-19_23-aprile-2020_appendix.pdf'}, { 'key': '2021051223100650000_79.10.1382.7', 'doi-asserted-by': 'crossref', 'unstructured': 'Ferner RE , Aronson JK . Chloroquine and hydroxychloroquine in covid-19. ' 'BMJ;1:m1432.doi:10.1136/bmj.m1432', 'DOI': '10.1136/bmj.m1432'}], 'container-title': 'Annals of the Rheumatic Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-217717', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 5, 13]], 'date-time': '2021-05-13T06:11:30Z', 'timestamp': 1620886290000}, 'score': 1, 'resource': {'primary': {'URL': 'https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217717'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 12]]}, 'references-count': 7, 'journal-issue': { 'issue': '10', 'published-online': {'date-parts': [[2020, 9, 14]]}, 'published-print': {'date-parts': [[2020, 10]]}}, 'alternative-id': ['10.1136/annrheumdis-2020-217717'], 'URL': 'http://dx.doi.org/10.1136/annrheumdis-2020-217717', 'relation': {}, 'ISSN': ['0003-4967', '1468-2060'], 'subject': [ 'General Biochemistry, Genetics and Molecular Biology', 'Immunology', 'Immunology and Allergy', 'Rheumatology'], 'container-title-short': 'Ann Rheum Dis', 'published': {'date-parts': [[2020, 5, 12]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0